CTIS2023-506976-28-00招募中1 期
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma - IPH6501-101
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Phase 1- Dose finding 1. Patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin's lymphoma (NHL) including the following types defined by WHO 2016: • Diffuse Large B Cell Lymphoma (DLBCL) NOS (Not otherwise specified) • High-grade B-cell lymphoma NOS • Primary mediastinal (thymic) large B-cell lymphoma • Follicular Lymphoma (FL) • Mantle cell lymphoma (MCL) • Marginal zone lymphoma (MZL) (nodal, extranodal or splenic) For the patients with indolent forms of NHL (i.e., FL, MZL) patients must meet criteria to receive systemic therapy, Phase 2- Dose expansion 2. Patients with advanced histologically confirmed, documented CD20+ B-cell NHL defined by WHO 2016., 3. Relapsed, progressive and/or refractory disease without established alternative therapy, 4. Must have received at least 2 prior systemic therapies including at a minimum anti-CD20 antibody therapy (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue., 5. Male or Female, at least 18 years of age, 6. Measurable disease defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension, 7. Eastern Cooperative Oncology Group (ECOG) performance status of = 2, 8. Must have a life expectancy of at least 12 weeks., 9. Toxicities due to prior therapy must be stable and recovered to = Grade 1 (except for clinically non- significant toxicities such as alopecia)
排除标准
- •1. Patients with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the Investigator to be of low likelihood for recurrence), 10. Major surgery within 4 weeks before the first dose of study drug or minor surgery within 1 week (subject must also have recovered from any surgery related toxicities to less than CTCAE Grade 2), 2. Prior chemotherapy, immunotherapy (tumor vaccine, cytokine or growth factor given to control the cancer) or other anti-cancer therapy within less than 4 weeks before study drug administration., 3. Autologous stem cell transplant or treatment with CAR-T (Chimeric Antigen Receptor T-Cell) cell therapy within 100 days prior to first dose of study drug, 4. Live vaccine = 6 weeks prior to first dose of study drug, 5. Use of other investigational drugs within 28 days, 6. Subjects with brain or subdural metastases are not eligible unless the metastases are asymptomatic and do not require treatment or have been adequately treated by local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks prior to study entry. In this protocol subjects with active brain metastasis are not eligible, 7. Current or past history of central nervous system (CNS) lymphoma, 8. Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Patients with a past history of stroke that have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits are allowed, 9. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)
研究者
相似试验
招募中
1 期
A trial to find the optimal dose of DB-OTO in infants and children with hearing loss (CHORD)Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)MedDRA version: 20.0Level: LLTClassification code: 10011874Term: Deaf Class: 10013993CTIS2024-511342-40-00Regeneron Pharmaceuticals Inc.22
进行中（未招募）
1 期
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined with Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-506820-10-00Genentech Inc.713
进行中（未招募）
1 期
A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia - ARGX-113-1804Primary Immune ThrombocytopeniaMedDRA version: 20.1Level: LLTClassification code 10074678Term: Primary immune thrombocytopenic purpuraSystem Organ Class: 100000004851EUCTR2019-000361-21-GBArgenx BVBA15
已完成
2 期
PHASE II OPEN LABEL, MULTI-CENTERIC CLINICAL TRIAL OF ORAL WCK 2349(1000 mg BID and 1200 mg BID)TO EVALUATE SAFETY AND EFFICACY IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA.CTRI/2011/09/002012Wockhardt Ltd120
进行中（未招募）
1 期
Phase 1/2 Study of CLN-081 in Patients with Lung Canceron-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002409-23-NLCullinan Oncology Inc.369